Venus Medical Aesthetics
Venus Legacy — RF Body Contouring
FDA-cleared multi-polar radiofrequency and PEMF technology — with documented therapeutic outcomes that extend substantially beyond conventional aesthetics.
Venus Legacy is an FDA-cleared medical device that combines Multi-Polar Radiofrequency (MP²) with Pulsed Electromagnetic Fields (PEMF) and VariPulse™ suction technology. This combination generates a volumetric heat field through the dermis and subcutaneous tissue — stimulating collagen production, improving circulation and remodelling connective tissue at depth.
The multi-polar RF creates uniform, deep thermal energy without the hot spots of older bipolar systems. The PEMF component works through a separate, non-thermal mechanism — stimulating fibroblast proliferation and promoting new capillary formation. Together they produce collagen remodelling and tissue regeneration at a depth not achievable through other non-invasive modalities.
At NuVue, Venus Legacy is delivered as part of a combined protocol with Advanced Lymphatic Drainage, across a larger treatment area than standard protocols — producing outcomes documented in a clinical paper published by Abby Mortimer in July 2026.
Consistent findings across our connective tissue disorder community, documented in clinical practice and published in July 2026.
The most striking finding in our cohort. Clients with hypertonic pelvic floor — many unable to achieve relaxation through physiotherapy alone — consistently release during Venus Legacy treatment to the abdomen and anterior thighs. This is a nervous system-level response: PEMF shifts the body from sympathetic dominance, resolving the upstream driver of the holding pattern rather than treating the pelvic floor directly.
The PEMF component modulates the autonomic nervous system toward parasympathetic activation. Clients consistently describe it as one of the only times their body "lets go." In a population characterised by chronic threat-state activation — structural instability, MCAS, dysautonomia — this autonomic shift is the gateway through which deeper therapeutic change becomes possible.
Venus Legacy creates a window of neuroplasticity by reducing the hypertonicity maintained by the nervous system as structural protection. Clients' capacity to engage with neuromuscular re-education is significantly enhanced following treatment — new movement patterns establish with greater ease and less discomfort. Due to the hypermobility factor, gains are maintained through an ongoing programme rather than a curative course.
MP² thermal energy reaches the deep anterior fascial chain when applied to the lower abdomen and upper anterior thigh — producing fascial softening at a depth not achievable through superficial manual techniques. Clients report significant and often immediate reduction in chronic anterior hip and groin tightness, with some reporting relief of referred inner thigh pain consistent with the anatomical distribution of the psoas.
Consistent improvement in GI symptoms — particularly constipation refractory to dietary management — following abdominal treatment. The mechanism is two-fold: PEMF-mediated vagal activation enhances the neural regulation of gut motility; and thermal relaxation of the abdominal bracing pattern restores mechanical freedom to GI structures. Clients describe their abdominal organs "settling" during treatment.
For lipoedema clients, the ability to receive effective treatment without a pain response is of profound clinical significance. Venus Legacy is consistently well-tolerated — many describe it as the first treatment they have received "without bracing." A treatment that doesn't provoke a distress response doesn't sustain the sympathetic dominance that perpetuates the lipoedema cycle of inflammation, lymphatic impairment and fascial fibrosis.
At NuVue, Venus Legacy is always paired with the NuVue Advanced Lymphatic Drainage method — and applied across a significantly larger treatment area than the standard manufacturer protocol.
Venus Legacy is delivered first: the thermal preparation softens fascial restriction, initiates autonomic down-regulation, and makes the tissue substantially more receptive to manual intervention. The ALD method then addresses the lymphatic and fascial component in tissue that has already been prepared — producing outcomes that neither modality achieves alone.
This sequencing creates a therapeutic window — a state of relative nervous system openness — in which change becomes accessible that would not be achievable while the nervous system remains in its habitual defensive mode.
We see a significant number of clients from the connective tissue disorder community — HSD, hEDS, POTS, MCAS, and lipoedema. These clients often arrive having exhausted standard therapeutic options and experienced provocation from well-intentioned treatment.
The NuVue approach is built around the understanding that these bodies need a different entry point — one that works with the nervous system rather than against it.
Pricing varies by location. Book online to view current availability and pricing for your clinic.
Book Online — View Pricing & AvailabilityNot sure where to start? A Lymphatic Assessment is recommended for all connective tissue disorder clients before commencing treatment.
A course of 6–8 sessions is typically recommended for aesthetic goals, with ongoing maintenance. For therapeutic clients, treatment frequency is determined by clinical presentation and discussed at assessment.
No. Venus Legacy is non-invasive and requires no recovery time. Temporary redness in the treated area resolves within an hour.
Yes — and it is one of the few treatment modalities that is both effective and consistently well-tolerated for this population. Thermal parameters are carefully managed and treatment is delivered in a rhythmic, non-compressive manner. We recommend a Lymphatic Assessment first for all CTD clients.
Yes. The multi-polar RF is effective across all skin types and skin tones.